MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

Search

MediciNova Inc

Ouvert

SecteurSoins de santé

1.24 1.64

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.21

Max

1.24

Chiffres clés

By Trading Economics

Revenu

-6.1B

-6.1B

Ventes

135K

135K

Marge bénéficiaire

-4,563,511.527

Employés

13

EBITDA

-405K

-3.6M

Dividendes

By Dow Jones

Prochains Résultats

11 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-4.4M

61M

Ouverture précédente

-0.4

Clôture précédente

1.24

Sentiment de l'Actualité

By Acuity

38%

62%

109 / 371 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

MediciNova Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 oct. 2025, 23:30 UTC

Actions en Tendance

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 oct. 2025, 21:21 UTC

Résultats

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 oct. 2025, 00:00 UTC

Acquisitions, Fusions, Rachats

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 oct. 2025, 23:40 UTC

Market Talk

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 oct. 2025, 23:39 UTC

Market Talk

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 oct. 2025, 23:29 UTC

Acquisitions, Fusions, Rachats

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 oct. 2025, 23:29 UTC

Acquisitions, Fusions, Rachats

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 oct. 2025, 23:29 UTC

Acquisitions, Fusions, Rachats

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 oct. 2025, 23:00 UTC

Market Talk

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 oct. 2025, 22:54 UTC

Market Talk
Acquisitions, Fusions, Rachats

Scales's JV Buyout Lauded by Bull -- Market Talk

2 oct. 2025, 22:54 UTC

Market Talk
Acquisitions, Fusions, Rachats

Global Forex and Fixed Income Roundup: Market Talk

2 oct. 2025, 22:46 UTC

Market Talk

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 oct. 2025, 22:46 UTC

Market Talk

Global Equities Roundup: Market Talk

2 oct. 2025, 21:17 UTC

Acquisitions, Fusions, Rachats

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 oct. 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Energy & Utilities Roundup: Market Talk

2 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 oct. 2025, 20:49 UTC

Acquisitions, Fusions, Rachats

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 oct. 2025, 20:00 UTC

Acquisitions, Fusions, Rachats

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 oct. 2025, 19:20 UTC

Market Talk

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 oct. 2025, 19:10 UTC

Market Talk

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 oct. 2025, 19:04 UTC

Market Talk

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 oct. 2025, 18:46 UTC

Acquisitions, Fusions, Rachats

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 oct. 2025, 18:46 UTC

Acquisitions, Fusions, Rachats

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 oct. 2025, 18:46 UTC

Acquisitions, Fusions, Rachats

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 oct. 2025, 18:45 UTC

Acquisitions, Fusions, Rachats

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 oct. 2025, 18:45 UTC

Acquisitions, Fusions, Rachats

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 oct. 2025, 18:44 UTC

Acquisitions, Fusions, Rachats

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 oct. 2025, 18:44 UTC

Acquisitions, Fusions, Rachats

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 oct. 2025, 18:44 UTC

Acquisitions, Fusions, Rachats

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 oct. 2025, 18:43 UTC

Acquisitions, Fusions, Rachats

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Comparaison

Variation de prix

MediciNova Inc prévision

Note du Consensus

By TipRanks

0 ratings

0

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

1.48 / 1.5599Support & Résistance

Court Terme

Weak Bearish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

109 / 371Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.
help-icon Live chat